Depending on the type of cancer, it can be used as monotherapy or combination as a part of first line regimen, maintenance regimen or relapsed settings
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene
Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market
Lenalidomide is used to treat cancer and also some anaemia disorders
Arrow is the marketing partner in US
Celgene will grant Sun Pharma a license to Celgene’s patents required to manufacture and sell certain generic lenalidomide capsules
Subscribe To Our Newsletter & Stay Updated
